| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Adherence to surgical care improvement project measures and the association with postoperative infections.
|
JAMA
|
2010
|
6.89
|
|
2
|
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
|
Int J Cancer
|
2007
|
2.00
|
|
3
|
Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System.
|
Blood
|
2003
|
1.92
|
|
4
|
Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry.
|
Surgery
|
2010
|
1.70
|
|
5
|
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
|
J Clin Oncol
|
2008
|
1.69
|
|
6
|
Multi-institutional phase I trials of anticancer agents.
|
J Clin Oncol
|
2008
|
1.65
|
|
7
|
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.
|
Neoplasia
|
2004
|
1.56
|
|
8
|
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2009
|
1.56
|
|
9
|
The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study.
|
J Urol
|
2006
|
1.45
|
|
10
|
Humans accumulate microsatellite instability with acquired loss of MLH1 protein in hematopoietic stem and progenitor cells as a function of age.
|
Blood
|
2012
|
1.45
|
|
11
|
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
|
Cancer Res
|
2004
|
1.45
|
|
12
|
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.44
|
|
13
|
Vancomycin-resistant enterococci infection: not just for the transplanted.
|
Leuk Lymphoma
|
2013
|
1.39
|
|
14
|
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
|
Thyroid
|
2009
|
1.35
|
|
15
|
Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice.
|
Cancer Res
|
2007
|
1.32
|
|
16
|
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
|
Thyroid
|
2013
|
1.19
|
|
17
|
Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma.
|
J Clin Oncol
|
2003
|
1.15
|
|
18
|
Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer.
|
Stem Cells
|
2002
|
1.14
|
|
19
|
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
|
Clin Cancer Res
|
2009
|
1.10
|
|
20
|
Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.
|
Lasers Surg Med
|
2010
|
1.07
|
|
21
|
Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.
|
Lung Cancer
|
2006
|
1.06
|
|
22
|
Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation.
|
Immunology
|
2013
|
1.06
|
|
23
|
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
|
Cancer Res
|
2011
|
1.04
|
|
24
|
Kangaroo Care modifies preterm infant heart rate variability in response to heel stick pain: pilot study.
|
Early Hum Dev
|
2009
|
1.04
|
|
25
|
Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults.
|
Br J Haematol
|
2004
|
1.03
|
|
26
|
Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
|
Br J Haematol
|
2007
|
1.03
|
|
27
|
Deregulation of FOXO3A during prostate cancer progression.
|
Int J Oncol
|
2009
|
1.02
|
|
28
|
Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
|
Carcinogenesis
|
2013
|
1.01
|
|
29
|
Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice.
|
FASEB J
|
2005
|
1.00
|
|
30
|
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
|
Cancer Res
|
2008
|
1.00
|
|
31
|
Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications.
|
J Am Acad Dermatol
|
2011
|
1.00
|
|
32
|
Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.
|
PLoS One
|
2013
|
0.99
|
|
33
|
Factors that affect skin aging: a cohort-based survey on twins.
|
Arch Dermatol
|
2009
|
0.98
|
|
34
|
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
|
Oncologist
|
2013
|
0.98
|
|
35
|
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
|
Biol Blood Marrow Transplant
|
2011
|
0.97
|
|
36
|
Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study.
|
Mol Carcinog
|
2011
|
0.95
|
|
37
|
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
|
Clin Cancer Res
|
2007
|
0.94
|
|
38
|
Direct comparison of umbilical cord blood versus bone marrow-derived endothelial precursor cells in mediating neovascularization in response to vascular ischemia.
|
Biol Blood Marrow Transplant
|
2006
|
0.94
|
|
39
|
REDOX regulation of IL-13 signaling in intestinal epithelial cells: usage of alternate pathways mediates distinct gene expression patterns.
|
Cell Signal
|
2010
|
0.94
|
|
40
|
Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model.
|
Pharm Res
|
2011
|
0.92
|
|
41
|
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
|
J Clin Oncol
|
2009
|
0.92
|
|
42
|
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
|
Oncol Rep
|
2011
|
0.91
|
|
43
|
Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.89
|
|
44
|
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
|
Invest New Drugs
|
2014
|
0.89
|
|
45
|
MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.
|
Hum Pathol
|
2013
|
0.88
|
|
46
|
Combined SCLC clinical and pathologic characteristics.
|
Clin Lung Cancer
|
2012
|
0.88
|
|
47
|
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.
|
PLoS One
|
2010
|
0.87
|
|
48
|
Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1.
|
Mol Carcinog
|
2012
|
0.87
|
|
49
|
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
|
Cancer Chemother Pharmacol
|
2009
|
0.87
|
|
50
|
Capacity building for the clinical investigation of AIDS malignancy in East Africa.
|
Cancer Detect Prev
|
2005
|
0.87
|
|
51
|
IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice.
|
Biol Direct
|
2012
|
0.86
|
|
52
|
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
|
Cancer Chemother Pharmacol
|
2007
|
0.86
|
|
53
|
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
|
Lung Cancer
|
2007
|
0.85
|
|
54
|
Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival.
|
J Thorac Cardiovasc Surg
|
2012
|
0.84
|
|
55
|
Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed.
|
Mol Cancer Ther
|
2013
|
0.84
|
|
56
|
Human β-defensin 3 peptide is increased and redistributed in Crohn's ileitis.
|
Inflamm Bowel Dis
|
2013
|
0.84
|
|
57
|
Recipient-specific tolerance after HLA-mismatched umbilical cord blood stem cell transplantation.
|
Transplantation
|
2005
|
0.84
|
|
58
|
PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.
|
Cancer Med
|
2015
|
0.83
|
|
59
|
Impairment of regulatory T-cell function in autoimmune thyroid disease.
|
Thyroid
|
2013
|
0.82
|
|
60
|
Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review.
|
Pituitary
|
2014
|
0.81
|
|
61
|
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.
|
Brachytherapy
|
2007
|
0.81
|
|
62
|
Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer.
|
Apoptosis
|
2014
|
0.80
|
|
63
|
Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
|
Brachytherapy
|
2007
|
0.80
|
|
64
|
Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.80
|
|
65
|
NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.
|
Am J Clin Pathol
|
2012
|
0.80
|
|
66
|
Phase I Clinical Trials in Patients ≥80.
|
J Geriatr Oncol
|
2011
|
0.79
|
|
67
|
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.79
|
|
68
|
Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome.
|
Biol Blood Marrow Transplant
|
2006
|
0.79
|
|
69
|
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
|
Invest New Drugs
|
2014
|
0.78
|
|
70
|
A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
|
Invest New Drugs
|
2013
|
0.78
|
|
71
|
Deficient IFN-gamma expression in umbilical cord blood (UCB) T cells can be rescued by IFN-gamma-mediated increase in NFATc2 expression.
|
J Clin Immunol
|
2003
|
0.78
|
|
72
|
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
|
Biol Blood Marrow Transplant
|
2005
|
0.78
|
|
73
|
Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.78
|
|
74
|
Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
|
Br J Haematol
|
2006
|
0.77
|
|
75
|
Effects of pimecrolimus versus triamcinolone on Langerhans cells after UV exposure.
|
Exp Dermatol
|
2010
|
0.77
|
|
76
|
A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging.
|
Surgery
|
2002
|
0.77
|
|
77
|
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
|
Leuk Lymphoma
|
2007
|
0.77
|
|
78
|
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
|
Arch Dermatol
|
2012
|
0.77
|
|
79
|
The functional duality of HoxB4 in hematopoietic reconstituting cells.
|
Cytometry A
|
2012
|
0.77
|
|
80
|
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer.
|
Invest New Drugs
|
2005
|
0.77
|
|
81
|
Maturation of the mucosal immune system underlies colitis susceptibility in interleukin-10-deficient (IL-10-/-) mice.
|
J Leukoc Biol
|
2007
|
0.77
|
|
82
|
Is response rate relevant to the phase II trial design of targeted agents?
|
J Clin Oncol
|
2008
|
0.76
|
|
83
|
Temporal evolution of patient characteristics enrolled on phase I trials.
|
Invest New Drugs
|
2009
|
0.75
|
|
84
|
Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.
|
Brachytherapy
|
2003
|
0.75
|
|
85
|
Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
|
Brachytherapy
|
2013
|
0.75
|
|
86
|
Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|